Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

2.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
2.3K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

305
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
305
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Noninvasive Wearable-Based Algorithm to Predict Worsening Heart Failure by Change in Natriuretic Peptide Levels.

JACC. Heart failure·2026
Same author

Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.

Circulation. Population health and outcomes·2026
Same author

Single center automated, multi-source deeply phenotyped heart transplant registry as a template to build tailored data infrastructure.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Comparative analysis of randomized versus real-world populations in heart failure: DIAMOND trial vs CARE-HK registry.

ESC heart failure·2026
Same author

Alerts Are Not Treatment: ALLEVIATE-HF and the Execution Gap in Heart Failure.

Journal of the American College of Cardiology·2026
Same author

Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF Trial.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.3K

Mechanically Reducing Cardiac Preload With the preCARDIA System in Acutely Decompensated Heart Failure.

Rayan Yousefzai1, Arvind Bhimaraj2, Michael S Kiernan3

  • 1DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA. Electronic address: https://twitter.com/RAYANYOUX.

JACC. Heart Failure
|December 13, 2025
PubMed
Summary
This summary is machine-generated.

The preCARDIA system demonstrated safety and feasibility in treating acute decompensated heart failure (ADHF). This novel device reduced cardiac filling pressures and increased urine output in patients, paving the way for further clinical trials.

Keywords:
acute decompensated heart failurecardiac preloadcongestiondevice therapy

More Related Videos

Continuous Venous-Arterial Doppler Ultrasound During a Preload Challenge
09:32

Continuous Venous-Arterial Doppler Ultrasound During a Preload Challenge

Published on: January 20, 2023

3.9K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Related Experiment Videos

Last Updated: Jan 7, 2026

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.3K
Continuous Venous-Arterial Doppler Ultrasound During a Preload Challenge
09:32

Continuous Venous-Arterial Doppler Ultrasound During a Preload Challenge

Published on: January 20, 2023

3.9K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Area of Science:

  • Cardiovascular Medicine
  • Medical Devices
  • Heart Failure Research

Background:

  • Acute decompensated heart failure (ADHF) is a critical condition often requiring interventions to manage elevated cardiac filling pressures.
  • The preCARDIA device offers a novel approach to mechanically reduce these pressures by regulating superior vena cava blood flow.

Purpose of the Study:

  • To evaluate the safety and feasibility of the next-generation preCARDIA system in patients with ADHF.
  • The VENUS-HF Early Feasibility Study (NCT03836079) assessed an updated preCARDIA system including sheath, catheter, and console modifications.

Main Methods:

  • A multicenter, prospective, single-arm study enrolled 60 subjects with ADHF.
  • Subjects received preCARDIA support for up to 24 hours, with safety and technical feasibility as primary endpoints.

Main Results:

  • The preCARDIA system showed high safety, with 98.3% freedom from major adverse events and 100% successful deployment/removal.
  • Significant reductions in right atrial pressure (23%) and pulmonary capillary wedge pressure (18%) were observed.
  • Net urine output increased by 1.9 L during 24-hour device use compared to the pre-treatment period.

Conclusions:

  • The preCARDIA system is a feasible and well-tolerated intervention for ADHF.
  • Early results indicate significant reductions in cardiac filling pressures and improved urine output.
  • Findings support larger trials, like the COR-ADHF trial, to confirm clinical efficacy.